Minnesota SF 364: Insulin products commissioner of health costs review authorization; excess costs determination; maximum reimbursement level establishment; appropriation

Status: Referred to Health and Human Services Finance and Policy (as of 2019-01-22)

State: Minnesota · Session: 2019-2020 · Bill: SF 364

Subjects: Drugs and Medicine

Sponsors: Little, Abeler, Eaton, Hayden, Marty

View Minnesota SF 364 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.